16 Jun 2026
Suven Life Sciences reported successful completion of the first-in-human Phase-1 study of SUVN-I6107, a muscarinic M1 positive allosteric modulator, with favourable safety, tolerability and pharmacokinetics.
The candidate now advances into Phase-2 development for cognitive disorders, deepening the company's central nervous system pipeline. Biomarker readouts pointed to increased alertness and information processing.